Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DANTROLENE SODIUM

All products: general benefit

Dantrium Capsules · DIN 01997602 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Dantrium Capsules · DIN 01997602 Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-01-27 · brand DANTRIUM CAPSULES · ATC M03CA01 DANTROLENE · form Capsule · route Oral · ingredients DANTROLENE SODIUM 25 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Dantrium Capsules: Formulary list price $0.7558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14019 · Verify on the e-Formulary ↗ (DIN 01997602)

Source record
DIN 01997602: Dantrium Capsules Raw flags: sec3=Y Item: 122000002; group id 242; item number 0433; lccId None; manufacturer id KNT Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.7558; ministry $0.7558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01997602 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14019
Shortage status: resolved shortage (ended 2024-02-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01997602
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (12:20 Skeletal Muscle Relaxants) and how they are covered

Matched class: 12:20 Skeletal Muscle Relaxants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): BACLOFEN 12:20 Skeletal Muscle Relaxants

BACLOFEN

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (16) · strengths: 2mg/mL, 0.05mg/mL, 0.5mg/mL, 10mg, 20mg · Inj Sol (Preservative-Free), Inj Sol-1mL Pk (Preservative-Free), Inj Sol-20mL Pk (Preservative-Free), Tab

CYCLOBENZAPRINE HCL

· 12 products · Listed, not a benefit · strengths: 10mg · Tab

ORPHENADRINE CITRATE

· 2 products · Listed, not a benefit · strengths: 60mg/2mL · Inj Sol-2mL Pk

TIZANIDINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 4mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:20
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DANTRIUM CAPSULES (dantrolene sodium capsules) is indicated for: • Controlling the manifestations of a chronic spasticity of skeletal muscle resulting from such conditions as spinal cord injury, cerebral palsy, multiple sclerosis, and stroke, whenever such spasticity results in a decrease in functional use of residual motor activity. • The pre-operative management of malignant hyperthermia-susceptible surgical patients. • The malignant hyperthermic crisis follow-up management of patients stabilized with the intravenous product (for information regarding the intravenous product see the Dosage and Administration section of the DANTRIUM INTRAVENOUS Product Monograph). DANTRIUM CAPSULES is not indicated in the relief of skeletal muscle spasms due to rheumatic disorders. 1.1 Pediatrics Pediatrics (5-18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of DANTRIUM CAPSULES in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use in this subpopulation (see 7.1.3 Pediatrics). Pediatrics (<5 years of age): Since there is insufficient experience with the … https://pdf.hres.ca/dpd_pm/00083295.PDF PM date: JAN 27, 2026 Source product: DANTRIUM CAPSULES; DIN 01997602; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.